<!doctype html>
<html>
 <head> 
  <meta content="width=device-width; ini&shy;tial-scale=1.0; maximum-scale=1.5; user-scalable=1;" name="viewport"> 
  <meta content="text/html; charset=UTF-8" http-equiv="Content-Type"> 
  <link rel="STYLESHEET" href="HighLight.css" type="text/css" charset="UTF-8"> 
  <link rel="STYLESHEET" href="ENAS5305.css" type="text/css" charset="UTF-8"> 
  <script src="jquery-2.0.31.min.js" type="text/javascript"></script> 
  <script src="HighlightSearch.js" type="text/javascript"></script> 
  <title>Bio&shy;mark. in Mets. BC_2017</title> 
 </head> 
 <body onload="_geturl1();"> 
  
  <p class="h1">1.0.0.0 Ab&shy;stract and Pub&shy;li&shy;ca&shy;tion</p> 
  <p class="text"><span class="bold">Pur&shy;pose</span><br> To up&shy;date guide&shy;line rec&shy;om&shy;men&shy;da&shy;tions on the role of bone-‍mod&shy;i&shy;fy&shy;ing agents in mul&shy;ti&shy;ple myelo&shy;ma.<br> &nbsp;</p> 
  <p class="text"><span class="bold">Meth&shy;ods</span><br> An up&shy;date panel con&shy;duct&shy;ed a tar&shy;get&shy;ed sys&shy;tem&shy;at&shy;ic lit&shy;er&shy;a&shy;ture re&shy;view by search&shy;ing PubMed and the Cochrane Li&shy;brary for ran&shy;dom&shy;ized con&shy;trolled tri&shy;als, sys&shy;tem&shy;at&shy;ic re&shy;views, meta-‍anal&shy;y&shy;ses, clin&shy;i&shy;cal prac&shy;tice guide&shy;lines, and ob&shy;ser&shy;va&shy;tion&shy;al stud&shy;ies.<br> &nbsp;</p> 
  <p class="text"><span class="bold">Re&shy;sults</span><br> Thir&shy;ty-‍five rel&shy;e&shy;vant stud&shy;ies were iden&shy;ti&shy;fied, and up&shy;dated ev&shy;i&shy;dence sup&shy;ports the cur&shy;rent rec&shy;om&shy;men&shy;da&shy;tions.<br> &nbsp;</p> 
  <p class="text"><span class="bold">Rec&shy;om&shy;men&shy;da&shy;tions</span><br> For pa&shy;tients with ac&shy;tive symp&shy;tomat&shy;ic mul&shy;ti&shy;ple myelo&shy;ma that re&shy;quires sys&shy;temic ther&shy;a&shy;py with or with&shy;out ev&shy;i&shy;dence of lytic de&shy;struc&shy;tion of bone or com&shy;pres&shy;sion frac&shy;ture of the spine from os&shy;teope&shy;nia on plain ra&shy;dio&shy;graph(s) or other imag&shy;ing stud&shy;ies, in&shy;tra&shy;venous ad&shy;min&shy;is&shy;tra&shy;tion of pamidronate 90 mg over at least 2 hours or zole&shy;dron&shy;ic acid 4 mg over at least 15 min&shy;utes every 3 to 4 weeks is rec&shy;om&shy;mend&shy;ed. Deno&shy;sum&shy;ab has shown to be non&shy;in&shy;fe&shy;ri&shy;or to zole&shy;dron&shy;ic acid for the pre&shy;ven&shy;tion of skele&shy;tal-‍re&shy;lat&shy;ed events and pro&shy;vides an al&shy;ter&shy;na&shy;tive. Fewer ad&shy;verse events re&shy;lat&shy;ed to renal tox&shy;i&shy;c&shy;i&shy;ty have been noted with deno&shy;sum&shy;ab com&shy;pared with zole&shy;dron&shy;ic acid and may be pre&shy;ferred in this set&shy;ting. The up&shy;date panel rec&shy;om&shy;mends that clin&shy;i&shy;cians con&shy;sid&shy;er re&shy;duc&shy;ing the ini&shy;tial pamidronate dose in pa&shy;tients with pre&shy;ex&shy;ist&shy;ing renal im&shy;pair&shy;ment. Zole&shy;dron&shy;ic acid has not been stud&shy;ied in pa&shy;tients with se&shy;vere renal im&shy;pair&shy;ment and is not rec&shy;om&shy;mend&shy;ed in this set&shy;ting. The up&shy;date panel sug&shy;gests that bone-‍mod&shy;i&shy;fy&shy;ing treat&shy;ment con&shy;tin&shy;ue for up to 2 years. Less fre&shy;quent dos&shy;ing has been eval&shy;u&shy;at&shy;ed and should be con&shy;sid&shy;ered in pa&shy;tients with re&shy;spon&shy;sive or sta&shy;ble dis&shy;ease. Con&shy;tin&shy;u&shy;ous use is at the dis&shy;cre&shy;tion of the treat&shy;ing physi&shy;cian and the risk of on&shy;go&shy;ing skele&shy;tal mor&shy;bid&shy;i&shy;ty. Retreat&shy;ment should be ini&shy;ti&shy;at&shy;ed at the time of dis&shy;ease re&shy;lapse. The up&shy;date panel dis&shy;cuss&shy;es mea&shy;sures re&shy;gard&shy;ing os&shy;teonecro&shy;sis of the jaw. Ad&shy;di&shy;tion&shy;al in&shy;for&shy;ma&shy;tion is avail&shy;able at <a href="https://www.asco.org/practice-guidelines/quality-guidelines/guidelines/hematologic-malignancies">www.asco.org/hematologic-malignanciesguide&shy;lines</a> and <a href="https://www.surveymonkey.com/r/guidelineevidence">www.asco.org/guide&shy;lineswiki.</a></p> 
  <p class="text">&nbsp;</p> 
  <p class="text"><span class="italic">J Clin Oncol 36:812-818. &copy; 2018 by Amer&shy;i&shy;can So&shy;ci&shy;ety of Clin&shy;i&shy;cal On&shy;col&shy;o&shy;gy</span></p> 
  <p class="text">&nbsp;</p> 
  <p class="text"><span class="bold">Role of Bone-‍Mod&shy;i&shy;fy&shy;ing Agents in Mul&shy;ti&shy;ple Myelo&shy;ma:Amer&shy;i&shy;can So&shy;ci&shy;ety of Clin&shy;i&shy;cal On&shy;col&shy;o&shy;gy Clin&shy;i&shy;cal Prac&shy;tice Guide&shy;line Up&shy;date</span></p> 
  <p class="text"><span class="italic">Ken&shy;neth An&shy;der&shy;son, Nofisat Is&shy;maila, Patrick J. Flynn, Susan Ha&shy;l&shy;abi, Sun&shy;dar Ja&shy;gan&shy;nath, Mo&shy;hammed S. Ogai&shy;ly, Jim Omel, Noop&shy;ur Raje, G. David Rood&shy;man, Gary C. Yee, and Robert A. Kyle</span></p> 
 <p class="text">Author affiliations and support information
    (if applicable) appear at the end of this
    article.</p>
  <p class="text">Pub&shy;lished at <a href="http://ascopubs.org/journal/jco">jco.org</a> on Jan&shy;uary 17, 2018.</p> 
  <p class="text">K.A and R.A.K. are Ex&shy;pert Panel co-‍chairs.</p> 
  <p class="text">Clin&shy;i&shy;cal Prac&shy;tice Guide&shy;line Com&shy;mit&shy;tee Ap&shy;proval: Septem&shy;ber 11, 2017</p> 
  <p class="text">Ed&shy;i&shy;tor&rsquo;s note: This Amer&shy;i&shy;can So&shy;ci&shy;ety of Clin&shy;i&shy;cal On&shy;col&shy;o&shy;gy (ASCO) Clin&shy;i&shy;cal Prac&shy;tice Guide&shy;line pro&shy;vides rec&shy;om&shy;men&shy;da&shy;tions, with com&shy;pre&shy;hen&shy;sive re&shy;view and anal&shy;y&shy;ses of the rel&shy;e&shy;vant lit&shy;er&shy;a&shy;ture for each rec&shy;om&shy;men&shy;da&shy;tion. Ad&shy;di&shy;tion&shy;al in&shy;for&shy;ma&shy;tion, in&shy;clud&shy;ing an ab&shy;bre&shy;vi&shy;at&shy;ed Data Sup&shy;ple&shy;ment with new stud&shy;ies, a Method&shy;ol&shy;o&shy;gy Sup&shy;ple&shy;ment, slide sets, clin&shy;i&shy;cal tools and re&shy;sources, and links to pa&shy;tient in&shy;for&shy;ma&shy;tion at www.can&shy;cer.net, is avail&shy;able at <a href="https://www.asco.org/practice-guidelines/quality-guidelines/guidelines/hematologic-malignancies">www.asco.org/hematologic-malignanciesguide&shy;lines</a> and <a href="https://www.surveymonkey.com/r/guidelineevidence">www.asco.org/guide&shy;lineswiki.</a></p> 
  <p class="text">Cor&shy;re&shy;spond&shy;ing au&shy;thor: Amer&shy;i&shy;can So&shy;ci&shy;ety of Clin&shy;i&shy;cal On&shy;col&shy;o&shy;gy, 2318 Mill Rd, Suite 800, Alexan&shy;dria, VA 22314; e-‍mail: <a href="mailto:guidelines@ asco.org">guide&shy;lines@asco.org</a>.</p> 
  <p class="text">&copy; 2018 by Amer&shy;i&shy;can So&shy;ci&shy;ety of Clin&shy;i&shy;cal On&shy;col&shy;o&shy;gy</p> 
  <p class="text">0732-183X/18/3608w-812w/$20.00</p> 
  
  <p class="h1">2.0.0.0 Sum&shy;ma&shy;ry of Rec&shy;om&shy;men&shy;da&shy;tion Table</p> 
  <p class="text">&nbsp;</p> 
  
  <table class="table"> 
   <colgroup> 
    <col width="40%"> 
    <col width="60%"> 
   </colgroup> 
   <tbody> 
    <tr> 
     <th class="table-header1" colspan="2"> <p class="table-title1-cent">THE ROLE OF BONE MOD&shy;I&shy;FY&shy;ING AGENTS IN MUL&shy;TI&shy;PLE MYELO&shy;MA: </p> <p class="table-title1-cent">AMER&shy;I&shy;CAN SO&shy;CI&shy;ETY OF CLIN&shy;I&shy;CAL ON&shy;COL&shy;O&shy;GY CLIN&shy;I&shy;CAL PRAC&shy;TICE GUIDE&shy;LINE UP&shy;DATE</p> </th> 
    </tr> 
    <tr> 
     <td class="col-blue1"> <p class="table-text"><span class="bold">In&shy;di&shy;ca&shy;tions to ini&shy;ti&shy;ate a BMA</span></p> </td> 
     <td class="col-blue1"> <p class="table-text"><span class="bold">Rec&shy;om&shy;men&shy;da&shy;tion</span></p> </td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">Pa&shy;tients with lytic dis&shy;ease on plain ra&shy;dio&shy;graphs or other imag&shy;ing stud&shy;ies</p> </td> 
     <td> <p class="table-text">For mul&shy;ti&shy;ple myelo&shy;ma pa&shy;tients who have, on plain ra&shy;dio&shy;graph(s) or other imag&shy;ing stud&shy;ies (MRI or CT Scan), lytic de&shy;struc&shy;tion of bone or com&shy;pres&shy;sion frac&shy;ture of the spine from os&shy;teope&shy;nia, in&shy;tra&shy;venous pamidronate 90 mg de&shy;liv&shy;ered over at least 2 hours or zole&shy;dron&shy;ic acid 4 mg de&shy;liv&shy;ered over at least 15 min&shy;utes every 3 to 4 weeks is rec&shy;om&shy;mend&shy;ed. Al&shy;ter&shy;na&shy;tive treat&shy;ment in&shy;cludes the use of deno&shy;sum&shy;ab, a mon&shy;o&shy;clon&shy;al an&shy;ti&shy;body tar&shy;get&shy;ing RANKL.</p> </td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">Pa&shy;tients with os&shy;teope&shy;nia in the ab&shy;sence of lytic dis&shy;ease</p> </td> 
     <td> <p class="table-text">Start&shy;ing bis&shy;pho&shy;s&shy;pho&shy;nates in pa&shy;tients with soli&shy;tary plas&shy;ma&shy;cy&shy;toma or smol&shy;der&shy;ing (asymp&shy;tomat&shy;ic) or in&shy;do&shy;lent myelo&shy;ma is not rec&shy;om&shy;mend&shy;ed.</p> </td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">Ad&shy;junct to pain con&shy;trol in pa&shy;tients with pain re&shy;sult&shy;ing from os&shy;te&shy;olyt&shy;ic dis&shy;ease and those re&shy;ceiv&shy;ing other in&shy;ter&shy;ven&shy;tions for frac&shy;tures or im&shy;pend&shy;ing frac&shy;tures</p> </td> 
     <td> <p class="table-text">In&shy;tra&shy;venous pamidronate or zole&shy;dron&shy;ic acid is rec&shy;om&shy;mend&shy;ed for pa&shy;tients with pain as a re&shy;sult of os&shy;te&shy;olyt&shy;ic dis&shy;ease and as an ad&shy;junc&shy;tive treat&shy;ment for pa&shy;tients re&shy;ceiv&shy;ing ra&shy;di&shy;a&shy;tion ther&shy;a&shy;py, anal&shy;gesics, or sur&shy;gi&shy;cal in&shy;ter&shy;ven&shy;tion to sta&shy;bi&shy;lize frac&shy;tures or im&shy;pend&shy;ing frac&shy;tures. Deno&shy;sum&shy;ab is an ad&shy;di&shy;tion&shy;al option.</p> </td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">Myelo&shy;ma pa&shy;tients with nor&shy;mal plain ra&shy;dio&shy;graph or os&shy;teope&shy;nia in bone min&shy;er&shy;al den&shy;si&shy;ty mea&shy;sure&shy;ments</p> </td> 
     <td> <p class="table-text">The Up&shy;date Panel sup&shy;ports start&shy;ing in&shy;tra&shy;venous bis&shy;pho&shy;s&shy;pho&shy;nates in mul&shy;ti&shy;ple myelo&shy;ma pa&shy;tients with os&shy;teope&shy;nia (os&shy;teo&shy;poro&shy;sis) but no ra&shy;dio&shy;graphic ev&shy;i&shy;dence of lytic bone dis&shy;ease.</p> </td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">Pa&shy;tients with mon&shy;o&shy;clon&shy;al gam&shy;mopa&shy;thy of un&shy;de&shy;ter&shy;mined sig&shy;nif&shy;i&shy;cance</p> </td> 
     <td> <p class="table-text">Start&shy;ing bis&shy;pho&shy;s&shy;pho&shy;nates in pa&shy;tients with mon&shy;o&shy;clon&shy;al gam&shy;mopa&shy;thy of un&shy;de&shy;ter&shy;mined sig&shy;nif&shy;i&shy;cance is not rec&shy;om&shy;mend&shy;ed un&shy;less os&shy;teope&shy;nia (os&shy;teo&shy;poro&shy;sis) exists.</p> </td> 
    </tr> 
    <tr> 
     <td rowspan="2"> <p class="table-text">Dos&shy;ing and Se&shy;lec&shy;tion of BMAs</p> </td> 
     <td> <p class="teble-text">As a re&shy;sult of in&shy;creased con&shy;cerns over renal ad&shy;verse events, dos&shy;ing guide&shy;lines for pa&shy;tients with pre-‍ex&shy;ist&shy;ing renal im&shy;pair&shy;ment were added to the zole&shy;dron&shy;ic acid pack&shy;age in&shy;sert. The guide&shy;lines rec&shy;om&shy;mend that pa&shy;tients with pre-‍ex&shy;ist&shy;ing mild-‍to-‍moderate renal im&shy;pair&shy;ment (es&shy;ti&shy;mat&shy;ed cre&shy;a&shy;ti&shy;nine clear&shy;ance, 30 to 60 mL/‍min) should re&shy;ceive a re&shy;duced dosage of zole&shy;dron&shy;ic acid. No changes in in&shy;fu&shy;sion time or in&shy;ter&shy;val are re&shy;quired. Zole&shy;dron&shy;ic acid has not been stud&shy;ied in pa&shy;tients with se&shy;vere renal im&shy;pair&shy;ment and is not rec&shy;om&shy;mend&shy;ed for use in these pa&shy;tients. Re&shy;cent data com&shy;par&shy;ing deno&shy;sum&shy;ab to zole&shy;dron&shy;ic acid has demon&shy;strat&shy;ed fewer ad&shy;verse events re&shy;lat&shy;ed to renal tox&shy;i&shy;c&shy;i&shy;ty with deno&shy;sum&shy;ab and this may be pre&shy;ferred in pa&shy;tients with com&shy;pro&shy;mised renal func&shy;tion.</p> </td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">Pamidronate 90 mg ad&shy;min&shy;is&shy;tered over 4 to 6 hours is rec&shy;om&shy;mend&shy;ed for pa&shy;tients with ex&shy;ten&shy;sive bone dis&shy;ease and ex&shy;ist&shy;ing se&shy;vere renal im&shy;pair&shy;ment (serum cre&shy;a&shy;ti&shy;nine level &gt;3.0 mg/dL [265 &mu;mol/‍L] or an es&shy;ti&shy;mat&shy;ed cre&shy;a&shy;ti&shy;nine clear&shy;ance &lt; 30 mL/‍min). Al&shy;though no dos&shy;ing guide&shy;lines are avail&shy;able for pa&shy;tients with pre-‍ex&shy;ist&shy;ing renal im&shy;pair&shy;ment, the Up&shy;date Panel rec&shy;om&shy;mends that clin&shy;i&shy;cians con&shy;sid&shy;er re&shy;duc&shy;ing the ini&shy;tial pamidronate dose in that set&shy;ting. In&shy;fu&shy;sion times less than 2 hours with pamidronate or less than 15 min&shy;utes with zole&shy;dron&shy;ic acid should be avoided.</p> </td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">Du&shy;ra&shy;tion of ther&shy;a&shy;py</p> </td> 
     <td> <p class="table-text">The Up&shy;date Panel sug&shy;gests that bone tar&shy;get&shy;ed treat&shy;ment con&shy;tin&shy;ue for a pe&shy;ri&shy;od of up to 2 years. Less fre&shy;quent dos&shy;ing has been eval&shy;u&shy;at&shy;ed and should be con&shy;sid&shy;ered in pa&shy;tients with re&shy;spon&shy;sive or sta&shy;ble dis&shy;ease. In pa&shy;tients who do not have ac&shy;tive myelo&shy;ma and are on main&shy;te&shy;nance ther&shy;a&shy;py, the physi&shy;cian may con&shy;sid&shy;er a 3 month in&shy;ter&shy;val of bis&shy;pho&shy;s&shy;pho&shy;nate ad&shy;min&shy;is&shy;tra&shy;tion. There are no data to sup&shy;port a more pre&shy;cise rec&shy;om&shy;men&shy;da&shy;tion for du&shy;ra&shy;tion of bis&shy;pho&shy;s&shy;pho&shy;nate ther&shy;a&shy;py in this group of pa&shy;tients. For those pa&shy;tients in whom bis&shy;pho&shy;s&shy;pho&shy;nates were with&shy;drawn after 2 years, the drug should be re&shy;sumed upon re&shy;lapse with new-‍onset skele&shy;tal-‍re&shy;lat&shy;ed events. Deno&shy;sum&shy;ab should not be stopped abrupt&shy;ly given its re&shy;versible mech&shy;a&shy;nism of action.</p> </td> 
    </tr> 
    <tr> 
     <td rowspan="5"> <p class="table-text">Mon&shy;i&shy;tor&shy;ing</p> </td> 
     <td> <p class="table-text">The Up&shy;date Panel rec&shy;om&shy;mends that serum cre&shy;a&shy;ti&shy;nine should be mon&shy;i&shy;tored be&shy;fore each dose of pamidronate or zole&shy;dron&shy;ic acid, in ac&shy;cor&shy;dance with FDA-‍ap&shy;proved la&shy;bel&shy;ing. Deno&shy;sum&shy;ab does not re&shy;quire mon&shy;i&shy;tor&shy;ing of renal func&shy;tion.</p> </td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">In pa&shy;tients who de&shy;vel&shy;op renal de&shy;te&shy;ri&shy;o&shy;ra&shy;tion with&shy;out ap&shy;par&shy;ent cause dur&shy;ing bis&shy;pho&shy;s&shy;pho&shy;nate ther&shy;a&shy;py, zole&shy;dron&shy;ic acid or pamidronate should be with&shy;held. Bis&shy;pho&shy;s&shy;pho&shy;nate ther&shy;a&shy;py can be re&shy;sumed, at the same dosage as that be&shy;fore treat&shy;ment in&shy;ter&shy;rup&shy;tion, when the serum cre&shy;a&shy;ti&shy;nine re&shy;turns to with&shy;in 10% of the base&shy;line level. Deno&shy;sum&shy;ab re&shy;quires no dose mod&shy;i&shy;fi&shy;ca&shy;tion.</p> </td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">Serum cal&shy;ci&shy;um should be mon&shy;i&shy;tored reg&shy;u&shy;lar&shy;ly and serum vi&shy;ta&shy;min D lev&shy;els should be eval&shy;u&shy;at&shy;ed in&shy;ter&shy;mit&shy;tent&shy;ly. Hypocal&shy;cemia is an ad&shy;verse ef&shy;fect of all bone re&shy;sorp&shy;tive agents and is more pro&shy;nounced with deno&shy;sum&shy;ab. Pa&shy;tients should be cal&shy;ci&shy;um and vi&shy;ta&shy;min D re&shy;pleted.</p> </td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">The Up&shy;date Panel also rec&shy;om&shy;mends in&shy;ter&shy;mit&shy;tent eval&shy;u&shy;a&shy;tion (every 3 to 6 months) of all pa&shy;tients re&shy;ceiv&shy;ing pamidronate or zole&shy;dron&shy;ic acid ther&shy;a&shy;py for the pres&shy;ence of al&shy;bu&shy;min&shy;uria on a spot urine sam&shy;ple. In pa&shy;tients ex&shy;pe&shy;ri&shy;enc&shy;ing un&shy;ex&shy;plained al&shy;bu&shy;min&shy;uria, then a 24-hour urine should be ob&shy;tained to as&shy;sess for &gt;500 mg/24 hours of uri&shy;nary al&shy;bu&shy;min, and dis&shy;con&shy;tin&shy;u&shy;a&shy;tion of the drug is ad&shy;vised until the renal prob&shy;lems are re&shy;solved. These pa&shy;tients should be reas&shy;sessed every 3 to 4 weeks (with a 24-hour urine col&shy;lec&shy;tion for total pro&shy;tein and urine pro&shy;tein elec&shy;trophore&shy;sis), and pamidronate should be re&shy;in&shy;sti&shy;tut&shy;ed over a longer in&shy;fu&shy;sion time (&geq;4 hours) and at doses not to ex&shy;ceed 90 mg every 4 weeks when the renal func&shy;tion re&shy;turns to base&shy;line.</p> </td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">The Up&shy;date Panel sup&shy;ports the use of screen&shy;ing uri&shy;nal&shy;y&shy;sis for pro&shy;teinuria but un&shy;der&shy;scores that a 24-hour urine col&shy;lec&shy;tion for de&shy;ter&shy;mi&shy;na&shy;tion of total pro&shy;tein and elec&shy;trophore&shy;sis is re&shy;quired if the test is pos&shy;i&shy;tive. Al&shy;though no sim&shy;i&shy;lar guide&shy;lines are avail&shy;able for zole&shy;dron&shy;ic acid, some Up&shy;date Panel mem&shy;bers rec&shy;om&shy;mend that zole&shy;dron&shy;ic acid be re&shy;in&shy;sti&shy;tut&shy;ed over a longer in&shy;fu&shy;sion time (&geq;30 min&shy;utes).</p> </td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">Bio&shy;chem&shy;i&shy;cal mark&shy;ers</p> </td> 
     <td> <p class="table-text">The use of the bio&shy;chem&shy;i&shy;cal mark&shy;ers of bone metabolism to mon&shy;i&shy;tor bone mod&shy;i&shy;fy&shy;ing ther&shy;a&shy;py use is not sug&shy;gest&shy;ed for rou&shy;tine care.</p> </td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">Os&shy;teonecro&shy;sis of the jaw</p> </td> 
     <td> <p class="table-text">Os&shy;teonecro&shy;sis of the jaw (ONJ) is an un&shy;com&shy;mon but po&shy;ten&shy;tial&shy;ly se&shy;ri&shy;ous com&shy;pli&shy;ca&shy;tion of in&shy;tra&shy;venous bis&shy;pho&shy;s&shy;pho&shy;nates and deno&shy;sum&shy;ab. The Up&shy;date Panel agrees with the rec&shy;om&shy;men&shy;da&shy;tions de&shy;scribed in the re&shy;vised FDA label for zole&shy;dron&shy;ic acid and pamidronate, Dear Doc&shy;tor let&shy;ters, a white paper, and var&shy;i&shy;ous po&shy;si&shy;tion pa&shy;pers or state&shy;ments. All pa&shy;tients should re&shy;ceive a com&shy;pre&shy;hen&shy;sive den&shy;tal ex&shy;am&shy;i&shy;na&shy;tion and ap&shy;pro&shy;pri&shy;ate pre&shy;ven&shy;tive den&shy;tistry be&shy;fore bone mod&shy;i&shy;fy&shy;ing ther&shy;a&shy;py. Ac&shy;tive oral in&shy;fec&shy;tions should be treat&shy;ed, and sites at high risk for in&shy;fec&shy;tion should be elim&shy;i&shy;nat&shy;ed. While on ther&shy;a&shy;py, pa&shy;tients should main&shy;tain ex&shy;cel&shy;lent oral hy&shy;giene and avoid in&shy;va&shy;sive den&shy;tal pro&shy;ce&shy;dures, if pos&shy;si&shy;ble. Con&shy;tin&shy;u&shy;a&shy;tion of a bone tar&shy;get&shy;ed agent in the set&shy;ting of ONJ has to be in&shy;di&shy;vid&shy;u&shy;al&shy;ized and de&shy;pen&shy;dent on a risk ben&shy;e&shy;fit ratio and sever&shy;i&shy;ty of bone dis&shy;ease.</p> </td> 
    </tr> 
   </tbody> 
   </table>
   
  <p class="h1">3.0.0.0 Im&shy;por&shy;tant Fig&shy;ures</p> 
  <p class="h2">3.1.0.0 Es&shy;ti&shy;mat&shy;ed Prices for Bone-‍Mod&shy;i&shy;fy&shy;ing Agents</p> 
   <table class="table">
   <colgroup> 
    <col width="30%"> 
    <col width="70%"> 
   </colgroup> 
   <tbody> 
    <tr> 
     <td colspan="2"> <p class="table-text"><span class="bold">Table 1.</span> Es&shy;ti&shy;mat&shy;ed Prices for Bone-‍Mod&shy;i&shy;fy&shy;ing Agents in the Unit&shy;ed States</p> </td> 
    </tr> 
    <tr> 
     <td class="col-gray1"> <p class="table-text">Agent (route)</p> </td> 
     <td class="col-gray1"> <p class="table-text">Bis&shy;pho&shy;s&shy;pho&shy;nate Pamidronate (in&shy;tra&shy;venous)</p></td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">Dose (mg)</p> </td> 
     <td> <p class="table-text">90</p> </td> 
    </tr> 
    <tr> 
     <td> <p class="teble-text">Sched&shy;ule</p> </td> 
     <td> <p class="table-text">De&shy;liv&shy;ered over no less than 2 hours every 3 or 4 weeks</p> </td> 
    </tr> 
    <tr> 
     <td><p class="teble-text">Price Per Dose (US dol&shy;lars)</p></td> 
     <td> <p class="table-text">$30.67*</p> </td> 
    </tr> 
    <tr> 
     <td><p class="teble-text">Total Price Per 1-Year Treat&shy;ment Cycle (US dol&shy;lars)</p></td> 
     <td> <p class="table-text">Every-‍4-‍weeks price: $398.71 ($30.67 &#x2715; 13)</p> </td> 
    </tr> 
    <tr> 
     <td class="col-gray1"> <p class="table-text">Agent (route)</p> </td> 
     <td class="col-gray1"> <p class="table-text">Bis&shy;pho&shy;s&shy;pho&shy;nate, Zole&shy;dron&shy;ic acid (in&shy;tra&shy;venous)</p></td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">Dose (mg)</p> </td> 
     <td> <p class="table-text">4</p> </td> 
    </tr> 
    <tr> 
     <td> <p class="teble-text">Sched&shy;ule</p> </td> 
     <td> <p class="table-text">De&shy;liv&shy;ered over no less than 15 min&shy;utes every 12 weeks or every 3-4 weeks</p> </td> 
    </tr> 
    <tr> 
     <td><p class="teble-text">Price Per Dose (US dol&shy;lars)</p></td> 
     <td> <p class="table-text">$53.64<span class="text-sup">&dagger;</span></p> </td> 
    </tr> 
    <tr> 
     <td><p class="teble-text">Total Price Per 1-Year Treat&shy;ment Cycle (US dol&shy;lars)</p></td> 
     <td> <p class="table-text">Every-‍12-‍weeks price: $214.56 ($53.64 &#x2715; 4)</p> <p class="table-text">Every-‍4-‍weeks price: $697.37 ($53.64 &#x2715; 13)</p> </td> 
    </tr> 
    <tr> 
     <td class="col-gray1"> <p class="table-text">Agent (route)</p> </td> 
     <td class="col-gray1"> <p class="table-text">Mon&shy;o&shy;clon&shy;al an&shy;ti&shy;body Deno&shy;sum&shy;ab (sub&shy;cu&shy;ta&shy;neous in&shy;jec&shy;tion)</p></td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">Dose (mg)</p> </td> 
     <td> <p class="table-text">120</p> </td> 
    </tr> 
    <tr> 
     <td> <p class="teble-text">Sched&shy;ule</p> </td> 
     <td> <p class="table-text">Every 4 weeks</p> </td> 
    </tr> 
    <tr> 
     <td><p class="teble-text">Price Per Dose (US dol&shy;lars)</p></td> 
     <td> <p class="table-text">$1,995.48<span class="text-sup">&Dagger;</span></p> </td> 
    </tr> 
    <tr> 
     <td><p class="teble-text">Total Price Per 1-Year Treat&shy;ment Cycle (US dol&shy;lars)</p></td> 
     <td> <p class="table-text">Every-‍4-‍weeks price: $25,941.24 ($1,995.48 &#x2715; 13)</p> </td> 
    </tr> 
   </tbody> 
  </table> 
  <div class="ref"> 
   <p class="reference">NOTE.Prices per dose were for a sin&shy;gle in&shy;fu&shy;sion or per sin&shy;gle in&shy;jec&shy;tion. Prices for drugs re&shy;im&shy;bursed through Medi&shy;care Part B only were iden&shy;ti&shy;fied from the sec&shy;ond quar&shy;ter 2017 Medi&shy;care Pay&shy;ment Al&shy;low&shy;able Part B Drugs Av&shy;er&shy;age Sales Price data. Drug price may vary by plan and by phar&shy;ma&shy;cy where a med&shy;i&shy;ca&shy;tion is filled (eg, pre&shy;ferred or nonpre&shy;ferred phar&shy;ma&shy;cies). Drug prices are dy&shy;nam&shy;ic, and thus the prices list&shy;ed in the table may not re&shy;flect cur&shy;rent prices. Bone-‍mod&shy;i&shy;fy&shy;ing treat&shy;ment con&shy;tin&shy;ue for a pe&shy;ri&shy;od of up to 2 years. Less-‍fre&shy;quent dos&shy;ing has been eval&shy;u&shy;at&shy;ed and should be con&shy;sid&shy;ered in pa&shy;tients with re&shy;spon&shy;sive or sta&shy;ble dis&shy;ease. Con&shy;tin&shy;u&shy;ous use is at the dis&shy;cre&shy;tion of the treat&shy;ing physi&shy;cian and the risk of on&shy;go&shy;ing skele&shy;tal mor&shy;bid&shy;i&shy;ty. Retreat&shy;ment should be ini&shy;ti&shy;at&shy;ed at the time of dis&shy;ease re&shy;lapse. While on ther&shy;a&shy;py, pa&shy;tients should main&shy;tain ex&shy;cel&shy;lent oral hy&shy;giene and avoid in&shy;va&shy;sive den&shy;tal pro&shy;ce&shy;dures.</p> 
   <p class="text">*$10.223/30 mg &#x2715; 3.</p> 
   <p class="text"> <span class="text-sup">&dagger;</span>$13.411/1 mg &#x2715; 4.</p> 
   <p class="text"> <span class="text-sup">&Dagger;</span>$16.629/1 mg &#x2715; 120.</p> 
   <p></p> 
  </div> 
  <p class="text">&nbsp;</p> 
  
  <p class="h1">4.0.0.0 AD&shy;DI&shy;TION&shy;AL RE&shy;SOURCES</p> 
  <p class="text"> More in&shy;for&shy;ma&shy;tion, in&shy;clud&shy;ing Data andMethod&shy;ol&shy;o&shy;gy Sup&shy;ple&shy;ments, slide sets, and clin&shy;i&shy;cal tools and re&shy;sources, is avail&shy;able at <a href="https://www.asco.org/practice-guidelines/quality-guidelines/guidelines/hematologic-malignancies"> www.asco.org/hematologic-malignancies-guide&shy;lines.</a> Pa&shy;tient in&shy;for&shy;ma&shy;tion is avail&shy;able at <a href="https://www.cancer.net/">www.can&shy;cer.net.</a> Visit <a href="https://www.surveymonkey.com/r/guidelineevidence">www.asco.org/guide&shy;lineswiki</a> to pro&shy;vide com&shy;ments on the guide&shy;line or to sub&shy;mit new ev&shy;i&shy;dence.</p> 
  <p class="text">&nbsp;</p> 
  
  <p class="h1">5.0.0.0 AU&shy;THOR CON&shy;TRI&shy;BU&shy;TIONS & AC&shy;KNOWL&shy;EDGE&shy;MENT</p> 
  <p class="text"> <span class="bold">Manuscript writing:</span>All au&shy;thors <br> <span class="bold">Final ap&shy;proval of manuscript:</span>All au&shy;thors <br> <span class="bold">Ac&shy;count&shy;able for all as&shy;pects of the work:</span>All au&shy;thors </p> 
  <p class="text">&nbsp;</p>
  <p class="text"> <span class="bold italic"> AC&shy;KNOWL&shy;EDG&shy;MENT</span></br> The Ex&shy;pert Panel wish&shy;es to thank Joseph Mikhael, MD, Sar&shy;ba&shy;jit Mukher&shy;jee, MD, and the Clin&shy;i&shy;cal Prac&shy;tice Guide&shy;lines Com&shy;mit&shy;tee for
        thought&shy;ful re&shy;views and in&shy;sight&shy;ful com&shy;ments on this guide&shy;line.</p>
  <p class="text">&nbsp;</p> 
  
  <p class="h1">6.0.0.0 Ap&shy;pen&shy;dix </p> 

  <p class="h1 ">7.0.0.0 Ap&shy;pen&shy;dix</p>

  <table class="table">
      <colgroup>
          <col width="30% " />
          <col width="36.67% " />
          <col width="33.33% " />
      </colgroup>
      <tbody>
          <tr>
              <td colspan="3 ">
              <p class="table-text-cent"><span class="bold ">Table A1.</span>Ex&shy;pert Panel Mem&shy;ber&shy;ship</p>
              </td>
          </tr>
          <tr>
              <td>
              <p class="table-text-cent ">Name (des&shy;ig&shy;na&shy;tion)</p>
              </td>
              <td>
              <p class="table-text-cent ">Aff&shy;ili&shy;ation/&#8203;‍Ins&shy;ti&shy;tu&shy;tion</p>
              </td>
              <td>
            <p class="table-text-cent ">Role/‍Area of Ex&shy;pertise</p>
            </td>
          </tr>
          <tr>
              <td class="col-gray1 ">
              <p class="table-text">Ken&shy;neth An&shy;der&shy;son, MD (co-‍chair)</p>
              </td>
              <td class="col-gray1 ">
              <p class="table-text">Dana-‍Far&shy;ber Can&shy;cer In&shy;sti&shy;tute, Boston, MA</p>
              </td>
              <td class="col-gray1 ">
                    <p class="table-text">Med&shy;i&shy;cal on&shy;col&shy;o&shy;gy</p>
                    </td>
          </tr>
          <tr>
              <td>
              <p class="table-text">Robert A. Kyle, MD (co-‍chair)</p>
              </td>
              <td>
              <p class="table-text">Mayo Clin&shy;ic, Rochester, MN</p>
              </td>
              <td>
                <p class="table-text">Hema&shy;tol&shy;o&shy;gy/on&shy;col&shy;o&shy;gy</p>
                </td>
          </tr>
          <tr>
              <td class="col-gray1 ">
              <p class="table-text">Patrick J. Flynn, MD</p>
              </td>
              <td class="col-gray1 ">
              <p class="table-text">Min&shy;neso&shy;ta On&shy;col&shy;o&shy;gy, Wood&shy;bury, MN</p>
              </td> <td class="col-gray1 ">
                    <p class="table-text">Hema&shy;tol&shy;o&shy;gy/on&shy;col&shy;o&shy;gy</p>
                    </td>
          </tr>
          <tr>
              <td>
              <p class="table-text">Sun&shy;dar Ja&shy;gan&shy;nath, MD</p>
              </td>
              <td>
              <p class="table-text">Mount Sinai Med&shy;i&shy;cal Cen&shy;ter, New York, NY</p>
              </td> <td>
                    <p class="table-text">Med&shy;i&shy;cal on&shy;col&shy;o&shy;gy</p>
                    </td>
          </tr>
          <tr>
              <td class="col-gray1 ">
              <p class="table-text">Susan Ha&shy;l&shy;abi, PhD</p>
              </td>
              <td class="col-gray1 ">
              <p class="table-text">Duke Uni&shy;ver&shy;si&shy;ty Med&shy;i&shy;cal Cen&shy;ter, Durham, NC</p>
              </td>
              <td class="col-gray1 ">
                    <p class="table-text">Bio&shy;sta&shy;tis&shy;tics/&#8203;‍epi&shy;dem&shy;io&shy;logy</p>
                    </td>
          </tr>
          <tr>
              <td>
              <p class="table-text">Noop&shy;ur Raje, MD</p>
              </td>
              <td>
              <p class="table-text">Mas&shy;sachusetts Gen&shy;er&shy;al Hos&shy;pi&shy;tal, Boston, MA</p>
              </td><td>
                    <p class="table-text">Hema&shy;tol&shy;o&shy;gy/on&shy;col&shy;o&shy;gy</p>
                    </td>
          </tr>
          <tr>
              <td class="col-gray1 ">
              <p class="table-text">David Rood&shy;man, MD, PhD</p>
              </td>
              <td class="col-gray1 ">
              <p class="table-text">In&shy;di&shy;ana Uni&shy;ver&shy;si&shy;ty School of Medicine, In&shy;di&shy;anapolis, IN</p>
              </td><td class="col-gray1 ">
                    <p class="table-text">Hema&shy;tol&shy;o&shy;gy/on&shy;col&shy;o&shy;gy</p>
                    </td>
          </tr>
          <tr>
              <td>
              <p class="table-text">Gary C. Yee, Phar&shy;mD</p>
              </td>
              <td>
              <p class="table-text">Uni&shy;ver&shy;si&shy;ty of Ne&shy;bras&shy;ka Med&shy;i&shy;cal Cen&shy;ter, Omaha, NE</p>
              </td><td>
                    <p class="table-text">Phar&shy;ma&shy;col&shy;o&shy;gy</p>
                    </td>
          </tr>
          <tr>
              <td class="col-gray1 ">
              <p class="table-text">Jim Omel, MD</p>
              </td>
              <td class="col-gray1 ">
              <p class="table-text">Ed&shy;u&shy;ca&shy;tion and Ad&shy;vo&shy;ca&shy;cy, Grand Is&shy;land, NE</p>
              </td><td class="col-gray1 ">
                    <p class="table-text">Pa&shy;tient rep&shy;re&shy;sen&shy;ta&shy;tive</p>
                    </td>
          </tr>
          <tr>
              <td>
              <p class="table-text">Mo&shy;hammed S. Ogai&shy;ly, MD</p>
              </td>
              <td>
              <p class="table-text">Beau&shy;mont Cen&shy;ter for Hema&shy;tol&shy;o&shy;gy and On&shy;col&shy;o&shy;gy–Down&shy;riv&shy;er
                    Brown&shy;stown , MI</p>
              </td><td><p class="table-text">Prac&shy;tice Guide&shy;lines Im&shy;ple&shy;men&shy;ta&shy;tion Net&shy;work
                    rep&shy;re&shy;sen&shy;ta&shy;tive</p>
              </td>
          </tr>
          <tr>
              <td class="col-gray1 ">
              <p class="table-text">Nofisat Is&shy;maila, MD</p>
              </td>
              <td class="col-gray1 ">
              <p class="table-text">Amer&shy;i&shy;can So&shy;ci&shy;ety of Clin&shy;i&shy;cal On&shy;col&shy;o&shy;gy, Alexan&shy;dria, VA</p>
              </td> <td class="col-gray1 ">
                    <p class="table-text">Staff/‍health re&shy;search method&shy;ol&shy;o&shy;gist</p>
                    </td>
          </tr>
          
      </tbody>
  </table>
  
  

  
   
  <p class="h1">7.0.0.0 Ab&shy;bre&shy;vi&shy;a&shy;tions</p> 
  <table class="table"> 
   <colgroup> 
    <col width="30% "> 
    <col width="70% "> 
   </colgroup> 
   <tbody> 
    <tr> 
     <td> <p class="table-text">BMA</p> </td> 
     <td> <p class="table-text">Bone-‍mod&shy;i&shy;fy&shy;ing agents</p> </td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">CT</p> </td> 
     <td> <p class="table-text">Com&shy;put&shy;ed&nbsp;to&shy;mog&shy;ra&shy;phy</p> </td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">FDA</p> </td> 
     <td> <p class="table-text">Food and Drug Ad&shy;min&shy;is&shy;tra&shy;tion</p> </td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">MRI</p> </td> 
     <td> <p class="table-text">Mag&shy;net&shy;ic res&shy;o&shy;nance imag&shy;ing</p> </td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">ONJ</p> </td> 
     <td> <p class="table-text">Os&shy;teonecro&shy;sis of the jaw</p> </td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">RANKL</p> </td> 
     <td> <p class="table-text">Re&shy;cep&shy;tor ac&shy;ti&shy;va&shy;tor of nu&shy;cle&shy;ar fac&shy;tor kappa-‍&Beta; lig&shy;and&nbsp;</p> </td> 
    </tr> 
    <tr> 
     <td> <p class="table-text">US</p> </td> 
     <td> <p class="table-text">Unit&shy;ed States</p> </td> 
    </tr> 
   </tbody> 
  </table>  
 </body>
</html> 